Novo Nordisk has just reported better-than-expected full-year results, with both revenues and profits lifted by 25% thanks to rocketing sales of its semaglutide GLP-1 agonist blockbusters, Ozempic for diabetes and Wegovy for obesity.
Novo Believes ‘Personalized’ Dosing Will Help CagriSema Shine
Investors sold off shares after Novo’s disappointing Cagrisema readout in December, but the company believes more trial results will show it can be the future of obesity treatment.
More from Earnings
• By
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
• By
Obefazimod has been heralded as a potential blockbuster for ulcerative colitis and there will be great interest in the readout of Phase III induction trials in the third quarter of this year.
• By
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
• By
CSL’s US influenza vaccine sales were a window into wider issues for vaccine manufacturers that had already impacted the fourth-quarter results of Merck, Pfizer and GSK. There could also be a correlation between lower vaccine sales and the measles outbreak in Texas.
More from Therapy Areas
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.